Sareum Hldgs Plc (SAR)
London Exchange · UK · prices in GBX · close of 15 Oct 2026
Key indicators
| Last close | GBX 27.50 |
|---|---|
| 52-week range | 11.75 – 40.00 |
| Return, 1 month / 3 months | −6.8% / +14.6% |
| Return, 1 year / 3 years | +69.2% / −62.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 35 |
| Volatility (1 year) | 69.0% |
| Worst drawdown (1 year) | -33.3% |
| Average daily value traded | 9.62M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sareum Holdings is a drug discovery and development company based in the United Kingdom. It designs small molecule kinase inhibitors, compounds that act on specific enzymes involved in disease processes. Its research focuses on treatments for cancer and autoimmune conditions, and it advances its programmes through partnerships and licensing arrangements with pharmaceutical companies. The company works at the early stages of medicine development, from laboratory discovery through to studies that prepare candidates for clinical testing.
The shares are listed on the London Exchange in UK under the code SAR, and the price on this page is in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sareum Hldgs Plc (SAR) trades on the London Exchange in UK. It last closed at GBX 27.50 on 15 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 888 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 69.2% and over the last three months it rose 14.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 75 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.0% | ||
| From 52-week high | -25.7% | ||
| Momentum | 89 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 14.6% | ||
| 6-month return | 31.0% | ||
| 12-month return, skipping the last month | 81.5% | ||
| Stability (higher is calmer) | 28 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 69.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.3% | ||
| Liquidity | 73 · Strong | Trades actively. | |
| Average daily value traded | 9.62M GBX | ||
| Zero-volume days | 8.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −6.8% |
| 3 months | +14.6% |
| 6 months | +31.0% |
| 1 year | +69.2% |
| 3 years | −62.1% |
| 5 years | −92.0% |
Signals
| 50-day / 200-day average | 29.82 / 22.18 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.30 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.